ClinicalTrials.gov
public full text
Public Domain
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
To evaluate the objective response rate of camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- French Clinical Datbase of Melanoma Patients (RIC-Mel)#454031
- Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma#14284
- High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma#369837
- Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases#1047417
- The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2#912825
Record · ID 860804
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive